<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">79811</article-id><article-id pub-id-type="doi">10.7554/eLife.79811</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>VPS9D1-AS1 overexpression amplifies intratumoral TGF-β signaling and promotes tumor cell escape from CD8<sup>+</sup> T cell killing in colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-274954"><name><surname>Yang</surname><given-names>Lei</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3718-2138</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279145"><name><surname>Dong</surname><given-names>Xichen</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279146"><name><surname>Liu</surname><given-names>Zheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279153"><name><surname>Tan</surname><given-names>Jinjing</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279147"><name><surname>Huang</surname><given-names>Xiaoxi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279148"><name><surname>Wen</surname><given-names>Tao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-279149"><name><surname>Qu</surname><given-names>Hao</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-279150"><name><surname>Wang</surname><given-names>Zhenjun</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Medical Research Center</institution>, <institution>Beijing Chao-Yang Hospital</institution>, <addr-line><named-content content-type="city">Beijing</named-content></addr-line>, <country>China</country></aff><aff id="aff2"><institution content-type="dept">Medical Research Center</institution>, <institution>Beijing Chao-Yang Hospital</institution>, <addr-line><named-content content-type="city">Beijign</named-content></addr-line>, <country>China</country></aff><aff id="aff3"><institution content-type="dept">Department of Cellular and Molecular Biology</institution>, <institution>Beijing Chest Hospital</institution>, <addr-line><named-content content-type="city">Beijing</named-content></addr-line>, <country>China</country></aff><aff id="aff4"><institution content-type="dept">Department of General Surgery</institution>, <institution>Beijing Chao-Yang Hospital</institution>, <addr-line><named-content content-type="city">Beijing</named-content></addr-line>, <country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-156274"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Reviewing editor</role><aff><institution>Shengjing Hospital of China Medical University</institution>, <country>China</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>yl6649084@mail.ccmu.edu.cn</email> (LY);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>13701320206@163.com</email> (HQ);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>drzhenjun@163.com</email> (ZW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>02</day><month>12</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e79811</elocation-id><history><date date-type="received"><day>27</day><month>04</month><year>2022</year></date><date date-type="accepted"><day>01</day><month>12</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Yang et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Yang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-79811-v1.pdf"/><abstract><p>Efficacy of immunotherapy is limited in patients with colorectal cancer (CRC) because high expression of tumor-derived transforming growth factor (TGF)-β pathway molecules and interferon (IFN)-stimulated genes (ISGs) promotes tumor immune evasion. Here, we identified a long noncoding RNA (lncRNA), VPS9D1-AS1, which was located in ribosomes and amplified TGF-β signaling and ISG expression. We show that high expression of VPS9D1-AS1 was negatively associated with T lymphocyte infiltration in two independent cohorts of CRC. VPS9D1-AS1 served as a scaffolding lncRNA by binding with ribosome protein S3 (RPS3) to increase the translation of TGF-β, TGFBR1, and SMAD1/5/9. VPS9D1-AS1 knockout downregulated OAS1, an ISG gene, which further reduced IFNAR1 levels in tumor cells. Conversely, tumor cells overexpressing VPS9D1-AS1 were resistant to CD8<sup>+</sup> T cell killing and lowered IFNAR1 expression in CD8<sup>+ </sup>T cells. In a conditional overexpression mouse model, VPS9D1-AS1 enhanced tumorigenesis and suppressed the infiltration of CD8<sup>+</sup> T cells. Treating tumor-bearing mice with antisense oligonucleotide drugs targeting VPS9D1-AS1 significantly suppressed tumor growth. Our findings indicate that the tumor-derived VPS9D1-AS1/TGF-β/ISG signaling cascade promotes tumor growth and enhances immune evasion and may thus serve as a potential therapeutic target for CRC.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81802349</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Lei</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>National Science Foundation of China</institution></institution-wrap></funding-source><award-id>8213234</award-id><principal-award-recipient><name><surname>Wen</surname><given-names>Tao</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Beijing Natural Science Foundation</institution></institution-wrap></funding-source><award-id>7192070</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Lei</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Beijing Municipal of Hospitals Incubating Program</institution></institution-wrap></funding-source><award-id>PX2018013</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Lei</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Scientific Research Project of Beijing Educational Committee</institution></institution-wrap></funding-source><award-id>KM20190025016</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Lei</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Open Project of Key Laboratory of Cardiovascular Disease Medical Engineering, Ministry of Education</institution></institution-wrap></funding-source><award-id>2019XXG-KFKT-03</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Lei</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal experimental protocols were approved (AEEI-2021-105) according to the guidelines of the Ethics Committee for Animal Testing of Capital Medical University.</p></fn><fn fn-type="other"><p>Human subjects: All sample donors provided informed consent, and the study was conducted under the approval  (2018-ke-24) of the Institutional Ethics Committee from Beijing Chaoyang Hospital of Capital Medical University between 2018 and 2020 samples were collected from patients with CRC who did not receive chemotherapy or radiotherapy before surgery.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>RNA sequencing data set of HCT116 sgControl and sgVPS cells were deposited in Sequence Read Archive (PRJNA716724) and Dryad Digital Repository (10.5061/dryad.qnk98sfk6).</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Lei Yang</collab><collab>Xichen Dong</collab><collab>Zheng Liu</collab><collab>Jinjing Tan</collab><collab>Xiaoxi Huang</collab><collab>Tao Wen</collab><collab>Hao Qu</collab><collab>Zhenjun Wang.</collab></person-group><year iso-8601-date="2021">2021</year><source>VPS9D1-AS1 regualtes differential mRNA in HCT116 cells</source><ext-link ext-link-type="uri" xlink:href="https://dataview.ncbi.nlm.nih.gov/object/PRJNA716724">https://dataview.ncbi.nlm.nih.gov/object/PRJNA716724</ext-link><comment>Sequence Read Archive, PRJNA716724</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Yang L</collab><collab>Dong X</collab><collab>Liu Z</collab><collab>Tan J</collab><collab>Huang X</collab><collab>Wen T</collab><collab>Qu H</collab><collab>Wang Z</collab></person-group><year iso-8601-date="2022">2022</year><source>Overexpression of VPS9D1-AS1, an activator of transforming growth factor β signaling, upregulates interferon-stimulated-gene expression to regress CD8+ T cell infiltration in the microenvironment of colorectal cancer.</source><ext-link ext-link-type="uri" xlink:href="https://dx.doi.org/10.5061/dryad.qnk98sfk6">https://dx.doi.org/10.5061/dryad.qnk98sfk6</ext-link><comment>Dryad Digital Repository, doi:10.5061/dryad.qnk98sfk6</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-79811-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>